ClinicalTrials.gg
RecruitingNCT07443774AdheRAUpdated Oct 2, 2026

Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence.

An observational study in ER+ Breast Cancer, Breast Cancer and Early Breast Cancer, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University Hospital, Grenoble · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 2, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
81
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,209 studies in Breast Neoplasms with a site in France — 207 open to participants now, 339 under way, 83 of them phase 3. Breast Neoplasms · France.

Planned enrollment
151st of 203
81 · median 200
Started
2026
with 43 others
Observational
204 of 1,209
44 open now
Primary completion
2031-04
later than 316 of 338 live
Registered
1,178th of 1,209
by date

Among the 1,209 studies in Breast Neoplasms with a site in France, this one is the 151st largest by planned enrollment of the 203 observational ones that give a count, is one of 44 that started in 2026, is one of 204 observational ones, reaches primary completion later than 316 of the 338 other live ones, and was the 1,178th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

207 of the 1,209 studies in Breast Neoplasms with a site in France are open now. Recruiting first, the newest first:

201 more — sign in →

All 207 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,209 studies in Breast Neoplasms with a site in France, or all of them as a file.
02

Study summary

Hormone receptor-positive (HR+) breast cancers represent the most common histological subtype of breast cancer, accounting for approximately 75% of cases, regardless of HER2 (human epidermal growth factor receptor 2) status (1). Adjuvant endocrine therapy (ET), including tamoxifen and aromatase inhibitors (AIs), is an effective pharmacological treatment for improving the prognosis of HR+ breast cancer, reducing the risk of recurrence by up to 50% (2-3-4-6). Despite its proven prognostic benefit, the full potential of endocrine therapy is not realized due to patient non-adherence (i.e., failure to comply with prescribed treatment). Adjuvant endocrine therapy is generally prescribed for a duration of 5 to 10 years. However, up to 40% of patients discontinue treatment prematurely, and 30% take the medication less frequently than prescribed. Poor adherence and low treatment persistence carry a substantial mortality burden: non-adherence is associated with a 49% increase in all-cause mortality. A retrospective analysis of a large database including more than 8,700 patients showed a 10-year survival rate of 80.7% among women who continued treatment, compared with 73.6% among those who discontinued adjuvant therapy prematurely (p \< 0.001). Among patients who continued treatment, the survival rate was 82% in those who were fully adherent, versus 78% in those who were only partially adherent (7-16).

The literature has documented a wide range of risk factors associated with non-adherence to or discontinuation of long-term adjuvant endocrine therapy. Treatment-related adverse effects, including hot flashes, joint stiffness, and sexual dysfunction, are common and may lead to treatment discontinuation. Fear of side effects may also prevent some patients from initiating or maintaining endocrine therapy. Others may not be fully convinced of the necessity of adjuvant endocrine therapy, particularly in the absence of overt signs of cancer. In addition, supportive care required to manage side effects is often inadequately reimbursed, making low income-combined with broader socioeconomic factors-a potential barrier to optimal adherence. Some patients may also experience difficulties remembering to take their medication regularly. The relative importance and contribution of these factors to non-adherence may evolve over time. Other factors may also play a role, including sociodemographic characteristics (low income, living alone, or unemployment).

Nevertheless, a residual risk of recurrence persists after five years of well-conducted standard endocrine therapy, extending up to two decades after diagnosis, particularly in patients with early-stage breast cancer stages II and III. In this higher-risk population, two phase III trials, monarchE and NATALEE, have recently evaluated the addition of a cell cycle inhibitor (CDK4/6 inhibitor) to standard adjuvant endocrine therapy and reported positive results with a reduction in the risk of relapse.

In the NATALEE trial, quality of life was assessed in all patients in the ribociclib plus aromatase inhibitor group (n = 2,549) versus the aromatase inhibitor alone group (n = 2,552). Mean scores did not differ significantly from baseline for any of the analyzed domains. Similarly, no significant change from baseline was observed in either treatment group.

However, it is important to note that 33.8% of patients discontinued ribociclib and 20% discontinued both endocrine therapy and ribociclib in the NATALEE trial, which is consistent with data from the literature.

In the monarchE trial, 16.6% of patients discontinued abemaciclib, and 6% discontinued both abemaciclib and endocrine therapy, while only 0.8% discontinued endocrine therapy in the control group. These findings are not consistent with previously published data.

To our knowledge, no real-world study has evaluated CDK4/6 inhibitors in combination with endocrine therapy in the adjuvant treatment of HR+/HER2-negative breast cancer.

AdheRA is a prospective multicenter cohort study of patients with early-stage HR+/HER2-negative breast cancer at high risk of recurrence, eligible for a combination of endocrine therapy and a CDK4/6 inhibitor such as abemaciclib or ribociclib in the adjuvant setting, aiming to assess treatment adherence and the reasons for non-adherence.

03

Conditions studied

  • ER+ Breast Cancer
  • Breast Cancer
  • Early Breast Cancer
  • Endocrine Therapy
  • Abemaciclib
  • Ribociclib

Browse trials for

Keywords

  • early breast cancer
  • celle cycle inhibitors
  • endocrine therapy
  • adjuvant setting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be selected from those with localized, high-risk, hormone receptor-positive, HER2-negative breast cancer who are treated at one of the two participating centers and receive adjuvant therapy between 2023 and 2028, and who are eligible for treatment with CDK4/6 inhibitors.

Patients will be seen in dedicated consultations, according to international recommendations, at least every six months, to assess treatment adherence, tolerability, and risk of recurrence. Recruitment will therefore take place directly during these consultations.

All patients for whom an indication for iCDK4/6 therapy is established will be eligible to participate in the study. This indication is determined during multidisciplinary tumor board meetings, which are standard practice in the patient care pathway.

The end of the inclusion period has been arbitrarily set five years later, in order to obtain a sufficient number of patients.

Eligibility criteria

Inclusion Criteria

  • Male or female patients aged ≥18 years.
  • Operable invasive breast carcinoma of no special type, hormone receptor-positive / -negative (estrogen receptor expression >10% with or without progesterone receptor expression >10%; HER2-negative defined as score 0, 1+, or 2+ non-amplified).
  • M0 disease according to the TNM 2018 classification.
  • Having undergone curative surgery of the primary breast tumor.
  • Having received radiotherapy, if indicated.
  • Indication for combined adjuvant endocrine therapy and iCDK4/6 therapy validated during a multidisciplinary tumor board meeting.
  • Initiation of adjuvant endocrine therapy combined with a CDK4/6 inhibitor between June 2023 and June 2028.
  • No objection to participation in the study.
  • Affiliation with the national health insurance system.

Non-Inclusion Criteria

  • Medical, geographical, sociological, psychological, or legal conditions that could prevent the patient from completing the study or from providing informed non-opposition.
  • Locally advanced, non-operable disease or disease not amenable to curative-intent treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
81 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to evaluate adherence to iCDK4/6 treatment in patients with localized hormone receptor-positive breast cancer at high risk of recurrence, within a real-world setting.

    The percentage of early discontinuation of iCDK4/6 therapy will be assessed. Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

    Time frame: Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

Secondary outcomes

  1. The objective is to estimate the proportion of patients who did not initiate iCDK4/6 therapy.

    The proportion of patients eligible for iCDK4/6 therapy who, in real-world clinical practice, did not initiate treatment.

    Time frame: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

  2. To estimate the mean treatment completion rate for iCDK4/6 therapy and endocrine therapy.

    2a. Percentage of completion of iCDK4/6 therapy (over the planned 2- or 3-year duration). 2b. Percentage of completion of endocrine therapy (over the planned 5-year duration, minimum required). 2c. Median duration of endocrine therapy and iCDK4/6 therapy.

    Time frame: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

  3. To estimate the proportion of dose modifications and to describe the reasons for these modifications.

    3a. Percentage of patients who experienced a dose reduction of iCDK4/6 therapy. 3b. Assessment of the reasons for iCDK4/6 dose reductions. 3c. Assessment of the reasons for iCDK4/6 treatment discontinuation.

    Time frame: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib.

  4. To describe risk factors associated with non-adherence.

    Collection and description of factors associated with non-adherence, including adverse events, physical activity, and sociodemographic factors.

    Time frame: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

  5. To evaluate invasive disease-free survival.

    Evaluation of invasive disease-free survival (iDFS).

    Time frame: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2031, 59 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 59 months is close to that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → May 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Mar 2, 2026
StartActual
May 26, 2026was Apr 2026
Primary completionEst.
Apr 2031
CompletionEst.
Dec 2031
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
CHU Grenoble Alpes is now Recruiting
Oct 2, 2026
Start date
Apr 1, 2026→May 26, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    CHU Grenoble Alpes is now Recruiting
    Start date Apr 1, 2026→May 26, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07443774
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
May 26, 2026
Primary completion
Apr 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 2, 2026

Study contacts

Emmanuelle JACQUET, MD, PhD
Contact
ejacquet1@chu-grenoble.fr
33 0)476765451
Adrien MONARD, PhD
Contact
adrien.monard@ghm-grenoble.fr
33 (0)4 76 70 70 22
Emmanuelle JACQUET
principal investigator · University Hospital, Grenoble

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion